REACHnet collaborates with partners locally and nationwide on patient-centered research. Here are a few of our projects.
Adult Congenital Heart Disease Study
The Adult Congenital Heart Disease (ACHD) study is led by the Louisiana Public Health Institute in partnership with Children’s National Hospital and seeks to establish a congenital heart disease (CHD) surveillance program through PCORnet to understand the impact of gaps in recommended care in CHD patients and create a cohort of patients of various CHD disease subtypes for prospective studies. Participating REACHnet sites include Ochsner Health and University of California at San Francisco.
The COVID-19 electronic healthcare data initiative project will demonstrate PCORnet sites’ ability to collect information on COVID data through the implementation of a nationally distributed data infrastructure. The collection of these COVID-19 data will help to answer critical questions to assist in the emergency response to the COVID-19 pandemic.
Louisiana Experiment Assessing Diabetes – Zero Dollar Copayment (LEAD-ZDC)
LEAD-ZDC is a prospective observational study to assess the effectiveness of zero dollar copayment for select common diabetes medications on patients’ medication adherence, blood glucose (A1c) control, diabetes complications, and healthcare utilization. Tulane University is leading the study in collaboration with Blue Cross Blue Shield of Louisiana and REACHnet partners in Louisiana.
The COVID-19 Citizen Science Study is recruiting patients into a digital cohort of “COVID-19 Citizen Scientists,” gathering patient-reported data, and linking with electronic health records to evaluate the impact of shelter-in-place policies and containment and mitigation strategies. The University of California at San Francisco is leading the study in partnership with Louisiana Public Health Institute and REACHnet partner health systems Ochsner Health and Baylor Scott & White Health.
The Healthcare Worker Exposure Response & Outcomes (HERO) study is a registry of over 45,000 healthcare workers nationwide. The study seeks to understand healthcare workers’ perspectives and experiences related to the COVID-19 pandemic by regularly collecting short surveys about current topics like vaccination, stress and burnout. The HERO Registry is open to anyone in the U.S. who works in any kind of first responder or healthcare setting.
The Multi-state EHR-based Network for Disease Surveillance (MENDS) is a CDC-funded initiative that seeks to test an automated chronic disease surveillance system using data routinely stored in health records to provide clinically detailed, efficient, and timely information from large, diverse populations with minimal added work and cost for health departments or clinicians.
The purpose of PREVENTABLE is to learn if taking a statin could help older adults, age 75+, live well for longer by preventing dementia, disability, or heart disease. PREVENTABLE is enrolling 20,000 participants nationwide. Participating REACHnet partners are: Ochsner Health, DHR Health, Baylor Scott & White Health, and University Medical Center New Orleans.
GUARDD-US is a pragmatic clinical trial enrolling patients of African ancestry with hypertension. Participants receive apolipoprotein L1 (APOL1) genetic testing, and the trial aims to determine the effect of returning APOL1 genetic risk information to patients and their primary care providers on systolic blood pressure (SBP). Participating from REACHnet are University Medical Center New Orleans and Baylor Scott & White Health.
The BP Control Lab, led by the University of California at San Francisco, involves three studies. The first describes blood pressure control in the United States using electronic health records from health systems across the country. The second compares blood pressure control between clinics that receive educational materials about blood pressure control guidelines with or without extra support from a site facilitator, trained by the American Medical Association, to improve their clinic processes and monitor how well clinics are controlling blood pressure. The third compares blood pressure control between patients who receive a home blood pressure monitor with and without a smartphone app.
Comparative Effectiveness of Pharmacogenomics for Treatment of Depression (CEPIO-D)
CEPIO-D is a prospective randomized trial to compare the effectiveness of combinatorial PGx-guided treatment versus best-practice guideline concordant treatment on well-being and depression severity in patients with major depressive disorder. REACHnet’s partner health system, University Medical Center New Orleans, is participating.
The LEAD Study is a prospective observational study examining the impacts of Medicare reimbursement for non-face-to-face chronic care management services on health outcomes among patients with type 2 diabetes. Tulane University is leading this project in collaboration with REACHnet partners in Louisiana.
ADAPTABLE is a clinical trial comparing the effectiveness of 81mg versus 325mg daily doses of aspirin to prevent heart attack and stroke in people living with heart disease. Results are now available on the study website.
REACHnet led a rapid cycle project titled “Using PCORnet to Monitor Provider and Patient Risk Factors Related to the Opioid Epidemic” to create an opioid surveillance database and address current gaps in timely access to clinical data necessary for surveillance, prevention, and intervention. The database includes information from electronic health records, insurance claims, state information about prescription medicines, results of drug tests, and information about people’s cause of death. Results and publications are available on the study page on PCORI’s website.
The PCORnet Bariatric Study compared benefits and risks of the three most common bariatric surgery procedures—Roux-en-y gastric bypass, adjustable gastric banding, and sleeve gastrectomy. The observational study used electronic health record (EHR) data for over 65,000 patients from 41 participating healthcare organizations across the country. Data were collected through the PCORnet distributed research infrastructure from several clinical research networks (CRNs), including REACHnet. Results and publications are available on the study page on PCORI’s website.
The ABX Study examined the effects of antibiotic use in the first two years of life on body mass index (BMI) at ages 5 and 10 years and on growth trajectories to age 5. The observational study used electronic health record (EHR) data for over 362,000 patients from 35 participating healthcare organizations nationwide. Data were collected through the PCORnet distributed research infrastructure from several clinical research networks (CRNs), including REACHnet. Results and publications are available on the study page on PCORI’s website.
REACHnet partnered with University of Florida on a study called “PCSK9 Inhibitor Use in the Real World: Data from the National Patient Centered Research Network (PCORnet)” which used electronic health record data to characterize the early utilization of PCSK9 inhibitors in addition to standard lipid lowering therapies among patients with varying degrees of cardiovascular risk. Data for this study were collected from eighteen geographically diverse healthcare systems. Results and publications are available on the study page on PCORI’s website.